Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors

Medical Hypotheses

Volumn 65, Issue 5, 2005, Pages 905-907

  Rubenstein, Marvin ^a,b   Tsui, Paulus ^a   Guinan, Patrick ^a,c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CISPLATIN; CYCLOPHOSPHAMIDE; GROWTH FACTOR; MESSENGER RNA; MITOXANTRONE; PACLITAXEL; RIBONUCLEASE H; ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR PROTEIN;

ARTICLE; BINDING SITE; CANCER; DEGRADATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFECTION; METABOLIC DISORDER; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN TARGETING; RNA TRANSLATION; START CODON; DRUG RESISTANCE; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENETICS; MALE; METABOLISM; METHODOLOGY;

MUS MUSCULUS;

ANDROGENS; BINDING SITES; DRUG RESISTANCE; GENE SILENCING; GENE TARGETING; GENE THERAPY; HUMANS; MALE; NEOPLASM PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSCRIPTION FACTORS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 27244440858     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2004.12.032     Document Type: Article

References (9)

1. P.C. Zamecnik, and M.L. Stephenson Inhibition of Rous sarcoma virus replication and transformation by a specific deoxynucleotide Proc Natl Acad Sci USA 75 1979 280 284
2. M. Rubenstein, P. Tsui, and P. Guinan A review of antisense oligonucleotides in the treatment of human disease Drug Future 29 2004 893 909
3. M. Rubenstein, G. Dunea, and P. Guinan Growth factor deprivation therapy utilizing antisense oligonucleotides DN&P 7 1994 517 524
4. M. Rubenstein, Y. Mirochnik, P. Chou, and P. Guinan Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice J Surg Oncol 62 1996 194 200
5. K. Yamanaka, H. Miyake, U. Zangemeister-wittke, B. Jansen, and M. Gleave Novel bispecific antisense oligonucleotides inhibiting both bcl-2 and bcl-xl expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells Proc Am Assoc Cancer Res 45 2004 [Abstract 2930]
6. M. Rubenstein, L. Slobodskoy, Y. Mirochnik, and P. Guinan Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol Med Oncol 20 2003 29 35
7. P. Tsui, M. Rubenstein, and P. Guinan Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model Med Oncol 21 2004 339 348
8. M. Rubenstein, Y. Mirochnik, P. Chou, and P. Guinan Growth factor deprivation therapy of hormone insensitive prostate and breast cancer utilizing antisense oligonucleotides Method Find Exp Clin Pharmacol 20 1998 825 831
9. M. Rubenstein, R. Glick, T. Lichtor, Y. Mirochnik, P. Chou, and P. Guinan Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-α and the epidermal growth factor receptor Med Oncol 18 2001 121 130